Entero Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Entero Therapeutics Inc.
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company’s programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Entero Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Entero Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Entero Therapeutics Inc. is ENTO:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Entero Therapeutics Inc. has its primary listing on NASDAQ (Small cap). You can trade Entero Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Entero Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Entero Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Entero Therapeutics Inc..